Jeff Jones is ranked #2405 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Jeff Jones (Oppenheimer) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Jeff Jones's stock ratings?

About 32% of Jeff's ratings were profitable over a one-year hold, with an average return of -7.8% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Jeff Jones

OPCO

Jeff Jones

Oppenheimer

Wall Street Analyst

★☆☆☆☆

#2405

on 13Foresight · ranked by our own returns

32%

Success Rate

-7.8%

Average Return

8 of 25 calls profitable · -14.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 32% of Jeff Jones's ratings turned a profit when each position was held for 1 year — averaging -7.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

88 Buy 10 Hold 0 Sell

Jeff's Stock Coverage 31 ratings · 2026-06-27

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
ALMS Alumis Inc.	Jun 26, 2026	BUY	Strong Buy +47.3% avg upside 11 analysts	$55.00 108.36% Upside	·
ODTX Odyssey Therapeutics, Inc.	Jun 18, 2026	BUY	Strong Buy +77.2% avg upside 5 analysts	$40.00 121.43% Upside	·
CRBP Corbus Pharmaceuticals	Jun 17, 2026	BUY	Strong Buy +309.9% avg upside 20 analysts	$52.00 495.01% Upside	·
ACRV Acrivon Therapeutics, Inc.	Jun 15, 2026	BUY	Strong Buy +771.7% avg upside 13 analysts	$8.00 376.18% Upside	·
AAPG Ascentage Pharma Group International Unsponsored ADR	Jun 15, 2026	BUY	Strong Buy +161.0% avg upside 10 analysts	$45.00 168.24% Upside	-0.6%
CATX Perspective Therapeutics	Jun 01, 2026	BUY	Strong Buy +269.3% avg upside 22 analysts	$13.00 327.57% Upside	-20.0%
AVBP ArriVent BioPharma, Inc.	Jun 01, 2026	BUY	Strong Buy +27.9% avg upside 15 analysts	$50.00 46.97% Upside	+3.5%
MDWD Mediwound	May 28, 2026	BUY	Strong Buy +42.5% avg upside 13 analysts	$32.00 110.64% Upside	-4.1%
CMMB Chemomab Therapeutics	May 15, 2026	BUY	Strong Buy +1611.8% avg upside 6 analysts	$25.00 1472.34% Upside	+3.6%
PTHS Pelthos Therapeutics	May 15, 2026	BUY	Strong Buy +96.0% avg upside 8 analysts	$66.00 127.40% Upside	-3.4%
CRVS Corvus Pharmaceuticals	May 15, 2026	BUY	Strong Buy +93.0% avg upside 14 analysts	$33.00 144.55% Upside	-2.5%
PHVS Pharvaris	May 13, 2026	BUY	Strong Buy +34.4% avg upside 14 analysts	$50.00 47.09% Upside	+1.4%
PMVP PMV Pharmaceuticals	May 13, 2026	BUY	Strong Buy +1136.1% avg upside 12 analysts	$5.00 320.24% Upside	+0.0%
ACRS Aclaris Therapeutics	May 08, 2026	BUY	Strong Buy +101.0% avg upside 15 analysts	$10.00 100.07% Upside	-12.4%
WHWK Whitehawk Therapeutics	May 08, 2026	BUY	Buy +212.8% avg upside 13 analysts	$7.00 68.35% Upside	+11.3%
PHAR Pharming Group	May 08, 2026	BUY	Strong Buy +189.8% avg upside 4 analysts	$40.00 199.78% Upside	-2.8%
IMCR Immunocore Holdings	Apr 20, 2026	BUY	Strong Buy +107.5% avg upside 22 analysts	$86.00 178.47% Upside	-10.8%
CLRB Cellectar Biosciences	Mar 02, 2026	HOLD	Strong Buy +3351.1% avg upside 7 analysts	—	-17.1%
KYMR Kymera Therapeutics	Feb 27, 2026	BUY	Strong Buy -9.4% avg upside 36 analysts	$120.00 11.03% Upside	+18.1%
ZURA Zura Bio	Aug 15, 2025	BUY	Strong Buy +180.8% avg upside 12 analysts	$16.00 199.16% Upside	+111.8%
ABEO Abeona Therapeutics	Aug 14, 2025	BUY	Strong Buy +204.0% avg upside 17 analysts	$20.00 256.45% Upside	-24.6%
PLRX Pliant Therapeutics	Aug 08, 2025	HOLD	Buy +1877.5% avg upside 21 analysts	—	-25.9%
MCRB Seres Therapeutics	Oct 29, 2024	HOLD	Buy +134.1% avg upside 11 analysts	—	+9.5%
ANTX AN2 Therapeutics, Inc.	Aug 14, 2024	HOLD	Buy +68.3% avg upside 7 analysts	—	+0.0%
MBRX Moleculin Biotech	Nov 30, 2023	BUY	Strong Buy +520.4% avg upside 5 analysts	—	-69.2%
BGMS Bio Green Med Solution	Nov 07, 2023	BUY	Strong Buy +2054.9% avg upside 7 analysts	—	-95.1%
NOVN Novan	Jul 18, 2023	HOLD	Buy 6 analysts	—	·
EVAX Evaxion Biotech	Apr 28, 2023	BUY	Strong Buy +304.7% avg upside 6 analysts	—	-66.8%
NTBLQ Notable Labs	Jul 20, 2022	HOLD	Buy +809999900.0% avg upside 12 analysts	—	·
TRVN Trevena	Sep 30, 2021	HOLD	Buy +949900.0% avg upside 11 analysts	—	·
JEF Jefferies	Jun 22, 2021	BUY	Hold -4.9% avg upside 9 analysts	$37.00 24.58% Downside	-6.9%

🔒 26 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Jeff Jones — Frequently Asked Questions

How accurate are Jeff Jones's stock ratings?

Based on the calls 13Foresight could measure, about 32% of Jeff's ratings were profitable over a one-year hold, with an average return of -7.8% per rating, or -14.3% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Jeff ranked on 13Foresight?

Jeff Jones is currently ranked #2405 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Jeff cover?

Jeff most recently has ratings on ALMS, ODTX, CRBP, ACRV, AAPG, CATX, AVBP, MDWD, CMMB, PTHS, CRVS, PHVS and 19 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!